USPTO Examiner HELM CARALYNNE E - Art Unit 1615

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19097443BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELSApril 2025September 2025Allow610YesNo
18950649BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELSNovember 2024February 2025Allow310NoNo
18475954ISOPROTERENOL COMPOSITIONS AND METHODSSeptember 2023October 2025Allow2410YesNo
18367206COMPOSITIONS AND METHODS FOR TREATING A DISORDER OR DEFECT IN SOFT TISSUESeptember 2023August 2025Abandon2311NoNo
18363526CORE-SHELL MICRONEEDLE PATCH FOR H2O2 AND PH CASCADE-TRIGGERED INSULIN DELIVERYAugust 2023January 2025Abandon1710NoNo
18225227COMPOSITIONS AND METHODS FOR TREATING EPILEPSYJuly 2023January 2024Allow620YesNo
18317436MODULATION OF SOLUBILITY, PALATABILITY, ABSORPTION, AND BIOAVAILABILITY OF MITRAGYNA SPECIOSA-DERIVED COMPOUNDS FOR ORAL AND BUCCAL DELIVERYMay 2023July 2024Abandon1520NoNo
18034159SANITARY PROCEDURES AND PRODUCTSApril 2023March 2026Abandon3501NoNo
18248075THERAPEUTIC AGENT FOR USE IN LOCAL TREATMENT OF INFLAMMATION ASSOCIATED WITH ATHEROSCLEROSIS AND/OR A THROMBOTIC STATEApril 2023January 2026Abandon3410NoNo
18108038METHOD OF MAKING AN OSTEOCONDUCTIVE FIBROUS ARTICLE AND A MEDICAL IMPLANT COMPRISING SUCH OSTEOCONDUCTIVE FIBROUS ARTICLEFebruary 2023July 2024Allow1720YesNo
18093240DEPOT FORMULATIONSJanuary 2023November 2024Abandon2310NoNo
18001843SENSITISER FOR CANCER TREATMENTDecember 2022November 2025Abandon3510NoNo
18001610LOW BURST-RELEASE LIRAGLUTIDE DEPOT SYSTEMSDecember 2022November 2025Abandon3510NoNo
18057021TOROIDAL MIXED NANOPARTICLE, METHOD FOR PREPARING THE SAME, AND METHOD FOR MULTIFUNCTIONAL DELIVERY USING THE SAMENovember 2022February 2026Allow3911YesNo
17998318NANOPARTICLES AS CARRIER-SYSTEM FOR ADJUVANTS/ANTIGENSNovember 2022October 2025Abandon3510NoNo
17911775Implantable Drug Delivery Devices For Localized Drug DeliverySeptember 2022November 2025Allow3810NoNo
17819981Cosmetic and Dermatological CompositionsAugust 2022September 2025Allow3741YesNo
17904140Compositions, Kits, Methods and Uses for Cleaning, Disinfecting, Sterilizing and/or TreatingAugust 2022January 2026Allow4120NoNo
17799059DISILVER HYDROGEN CITRATE-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, ANTIBACTERIAL AGENT OR ANTIVIRAL AGENT USING SAME, AND METHOD FOR PRODUCING SAMEAugust 2022December 2025Allow4020NoNo
17882552DRUG DELIVERY METHODS, STRUCTURES, AND COMPOSITIONS FOR NASOLACRIMAL SYSTEMAugust 2022April 2024Abandon2010NoNo
17750865TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOFMay 2022February 2024Abandon2110NoNo
17724378COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUNDApril 2022January 2024Abandon2110NoNo
17716443SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS TO ENHANCE IMMUNE TOLERANCEApril 2022January 2025Abandon3420NoNo
17706869TOPICAL PAIN PATCHMarch 2022January 2025Abandon3310NoNo
17698389Curcumin SolubilisateMarch 2022January 2024Abandon2210NoNo
17698451HIGH-CONCENTRATION FLUENSULFONE FORMULATIONS, THEIR USES AND PROCESSES OF PREPARATIONMarch 2022October 2024Abandon3120NoNo
17693904POROUS BIOCOMPATIBLE IMPLANT WITH EXCELLENT OSSEOINTEGRATION AND METHOD FOR MANUFACTURING SAMEMarch 2022November 2024Abandon3221NoNo
17690837METHODS FOR RELIEVING BACK PAIN WITH TERMINALIA CHEBULA COMPOSITIONSMarch 2022September 2024Abandon3120NoNo
17687534METHODS OF USING RIFAMYCIN SV FOR THE TREATMENT OF SICKLE CELL DISEASEMarch 2022November 2023Abandon2110NoNo
17672651ANTIBACTERIAL OR ANTIFUNGAL COMPOSITIONFebruary 2022January 2025Allow3530NoNo
17587170INHALATION OF NITRIC OXIDEJanuary 2022October 2024Abandon3320NoNo
17581820Collagen Membrane or Matrix with Antimicrobial PropertiesJanuary 2022November 2024Abandon3421NoNo
17627810APPLICATION OF CARBON-BASED NANOMATERIAL IN PREPARATION OF DRUG FOR RELIEVING OR TREATING HDJanuary 2022October 2025Abandon4521NoNo
17627474COMPOSITION AND METHODS FOR THE TREATMENT OF SKIN CONDITIONSJanuary 2022May 2025Abandon4011NoNo
17626741ORAL DISODIUM PYROPHOSPHATE FOR USE IN REDUCING CALCIFICATIONJanuary 2022December 2023Abandon2301NoNo
17569586Compositions and Methods for Treating a Disorder or Defect in Soft TissueJanuary 2022October 2023Abandon2101NoNo
17596946BEVERAGE FORTIFIED WITH FERROUS BISGLYCINATEDecember 2021February 2025Abandon3810NoNo
17596945BEVERAGE FORTIFIED WITH FERROUS BISGLYCINATEDecember 2021February 2025Abandon3810NoNo
17621035SUN CARE COMPOSITIONS WITH UV REFLECTIVE PARTICLESDecember 2021August 2025Abandon4420NoNo
17620571CONSTITUENT FOR PREVENTING AND/OR TREATING SKIN WOUNDSDecember 2021December 2024Allow3610YesNo
17553605Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their PreparationDecember 2021December 2024Abandon3621NoNo
17618695WOUND-TREATING GAS COMPOSITION, AND WOUND-TREATING APPARATUSDecember 2021March 2026Abandon5140YesNo
17545588CRACKLING HAND SANITIZER FORMULATIONS AND ASSOCIATED METHODSDecember 2021March 2024Abandon2720YesNo
17616633NON-NATURAL INSECT PHEROMONE BLEND COMPOSITIONSDecember 2021May 2025Abandon4201NoNo
17615940BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELSDecember 2021October 2024Allow3431YesNo
17614386GLYCEROL AND SODIUM PENTABORATE BASED FORMULATION PREVENTING POSTOPERATIVE ADHESIONSNovember 2021November 2024Allow3610YesNo
17611975Use of metal ions to potentiate the therapeutic effects of arsenicNovember 2021April 2025Abandon4101NoNo
17527465Cannabinoid EmulsifierNovember 2021September 2024Allow3431YesNo
17611234ANTIMICROBIAL NANOCLAYS COMPRISING CATIONIC ANTIMICROBIALS, METHOD OF PREPARATION AND USES THEREOFNovember 2021February 2026Abandon5121NoNo
17610734AQUEOUS LIQUID COSMETICNovember 2021December 2024Allow3710YesNo
17496515BIODEGRADABLE CHITOSAN MICRONEEDLE PATCH FOR TRANSDERMAL DELIVERY FOR LIVESTOCK PAIN MANAGEMENTOctober 2021June 2025Abandon4440NoNo
17490190ANTIBACTERIAL ANTIVIRAL TREATED FABRICSSeptember 2021December 2023Abandon2601NoNo
17488787CAPSULE WITH INTERNAL DIAPHRAGM FOR IMPROVED BIOAVAILABILITYSeptember 2021April 2024Abandon3020NoNo
17399709COMPOSITIONS COMPRISING DEAD SEA WATER AND POLYSACCHARIDES AND USES THEREOF AS SKIN PROTECTANTSAugust 2021February 2024Allow3011YesNo
17398173METHOD FOR TREATING CARDIAC CONDITIONS WITH PLACENTA-DERVIVED COMPOSITIONSAugust 2021June 2024Abandon3421NoNo
17428685PHOTO-PROTECTIVE PLANT-DERIVED COMPOSITIONAugust 2021September 2024Abandon3801NoNo
17428334IMPROVED ENDOSCOPE DISINFECTANTAugust 2021June 2025Allow4670YesNo
17389719DIETARY MACRO/MICRONUTRITIONAL SUPPLEMENT FOR PATIENTS UNDERGOING KIDNEY DIALYSISJuly 2021July 2023Abandon2310NoNo
17384145ANTITHROMBOTIC COATING COMPOSITION AND ANTITHROMBOTIC COATING METHOD USING SAMEJuly 2021September 2023Abandon2510NoNo
17384198ANTIMICROBIAL COATING COMPOSITION AND ANTIMICROBIAL COATING METHOD USING SAMEJuly 2021September 2023Abandon2610NoNo
17367254Novel Isoquinoline Derivative, Preparing Method Thereof, and Pharmaceutical Composition for Preventing or Treating Autophagy Related Diseases Containing the Same as an Active IngredientJuly 2021February 2023Allow1911NoNo
17416851SPRAYING AGENT COMPRISING PESTICIDEJune 2021December 2024Allow4220YesNo
17416568COSMETIC COMPOSITION COMPRISING HYDROSOLUBLE UV FILTERSJune 2021October 2025Abandon5240NoNo
17343169PROCESS FOR MANUFACTURING PHENYLEPHRINE RESINATE PARTICLES; PHENYLEPHRINE RESINATE PARTICLES; AND USE OF PHENYLEPHRINE RESINATE PARTICLES IN PHARMACEUTICAL FORMULATIONSJune 2021September 2023Abandon2710NoNo
17292536UMECLIDINIUM AND VILANTEROL FORMULATION AND INHALERMay 2021June 2025Abandon5020NoYes
17306053SURGICAL SYSTEM AND METHODS OF USEMay 2021September 2024Allow4120YesNo
17290212COMPOSITION OF ACTIVE INGREDIENTS AS BOOSTER FOR UV-FILTERSApril 2021June 2025Abandon5020NoNo
17268061COSMETICApril 2021September 2025Allow5540NoNo
17287949NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMESApril 2021July 2025Abandon5111NoNo
17282332METHOD AND COMPOSITION FOR RELIEVING FATIGUE AND RESTORING ENERGYApril 2021July 2024Abandon4010NoNo
17218960COSMETIC COMPOSITION WITH GLAUCINE, RETINOL AND PEPTIDES TO COMBAT SKIN AGINGMarch 2021October 2024Abandon4240YesNo
17281553Aqueous Formulations Containing Povidone Iodine for Effective Treatment and Prevention of Virus InfectionsMarch 2021October 2025Abandon5421NoNo
17279886TITANIUM DIOXIDE DISPERSIONMarch 2021January 2025Abandon4620NoNo
17210747COMPOSITIONS COMPRISING CARUM CARVI AND ROSMARINUS OFFICINALIS EXTRACTS AND METHODS OF USING SAMEMarch 2021April 2025Abandon4840NoNo
17209645COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASE BY CONTACT LENS MEDIATED DRUG DELIVERYMarch 2021November 2023Abandon3120NoNo
17208381Compositions and Methods for Treatment of Ocular ConditionsMarch 2021January 2025Abandon4641YesNo
17207337DEVICE AND METHOD FOR TREATING INFECTIONSMarch 2021September 2024Abandon4201NoNo
17205630TENT WITH ANTIMICROBIAL TREATMENT APPLIED THERETO AND METHOD OF IMPARTING ANTIMICROBIAL PROPERTIES TO THE TENTMarch 2021December 2023Abandon3330NoNo
17199518SUSTAINED-RELEASE PARTICLES AND PRODUCTION METHOD THEREOFMarch 2021August 2025Abandon5361YesNo
17198211BIOMIMETIC ELECTRICALLY CONDUCTIVE HYALURONIC ACID-BASED HYDROGELSMarch 2021October 2023Allow3121NoNo
17196953IMPLANTABLE SUSTAINED RELEASE DEVICE AND A METHOD OF USE THEREFOR IN THE TREATMENT OF BRAIN DISORDERSMarch 2021November 2023Allow3211YesNo
17180161Kill and Protect Surface Disinfectant and Hand Sanitizer for Combatting Contact Infection SpreadFebruary 2021June 2024Abandon4020YesYes
17179078Isoproterenol Compositions and MethodsFebruary 2021July 2023Allow2850YesYes
17175172METHODS OF TREATMENT WITH BUPRENORPHINEFebruary 2021March 2023Abandon2501NoNo
17174107METHOD OF WEIGHT REGULATION USING NEBULIZED NICOTINEFebruary 2021April 2024Abandon3820NoNo
17264937INJECTABLE PROLONGED-ACTION COMPOSITIONS FOR USE IN THE TREATMENT OF NAIL DISEASE AND/OR FOR PROMOTING NAIL GROWTHFebruary 2021October 2025Abandon5621NoNo
17158786METHODS AND COMPOSITIONS TO MODULATE THE GUT MICROBIOTA AND TO MANAGE WEIGHTJanuary 2021December 2025Abandon5951YesYes
17156892PREPARATION CONTAINING 6,7-UNSATURATED-7-CARBAMOYL MORPHINAN DERIVATIVESJanuary 2021April 2025Allow5150YesNo
17150246CHEMICAL VAPOR DEPOSITION OF POLYMER COATINGS FOR CONTROLLED DRUG RELEASE, ASSEMBLIES CONTAINING SAME, AND METHODS OF PRODUCTION AND USE THEREOFJanuary 2021November 2023Abandon3420NoNo
17145056INHIBITION OF CANDIDA AURIS BIOFILM FORMATION ON MEDICAL AND ENVIRONMENTAL SURFACES BY SILVER NANOPARTICLESJanuary 2021May 2023Abandon2911NoNo
17142725SURGICAL SYSTEM AND METHODS OF USEJanuary 2021May 2024Abandon4040YesNo
17141609ZN-GA SERIES ALLOY AND ITS PREPARATION METHOD AND APPLICATIONJanuary 2021May 2023Abandon2801NoNo
17107544HYDROGEL/NANOPARTICLE COMPLEX WITH TEMPERATURE SOL-GEL TRANSITION FOR SUSTAINED DRUG RELEASENovember 2020May 2024Abandon4131NoNo
17056602ANTIMICROBIAL COMPOSITION BASED ON POLYPHENOLS AND POLYSACCHARIDES, METHOD FOR PREPARING THEREOF AND USE OF THE SAMENovember 2020April 2024Abandon4101NoNo
17053870DEPOT ADMINISTRATION OF ILOPERIDONENovember 2020May 2024Abandon4221NoNo
17050230TETRABENAZINE TRANSDERMAL DELIVERY DEVICEOctober 2020July 2024Allow4511YesNo
17073332OXYGEN-RELEASING BIOMATERIALS, ARTICLES AND METHODSOctober 2020January 2026Abandon6010NoNo
17069587CONDUCTIVE POLYMER MICRONEEDLE ARRAYS FOR ELECTRONICALLY-CONTROLLED DRUG RELEASEOctober 2020November 2022Allow2501YesNo
17047054AQUEOUS HYPOHALOUS ACID PREPARATIONS FOR THE INACTIVATION OF RESISTANT INFECTIOUS AGENTSOctober 2020September 2025Abandon5931NoNo
17063095DEPOT FORMULATIONSOctober 2020April 2023Abandon3010NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HELM, CARALYNNE E.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
38
Examiner Affirmed
34
(89.5%)
Examiner Reversed
4
(10.5%)
Reversal Percentile
23.5%
Lower than average

What This Means

With a 10.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
148
Allowed After Appeal Filing
18
(12.2%)
Not Allowed After Appeal Filing
130
(87.8%)
Filing Benefit Percentile
15.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 12.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HELM, CARALYNNE E - Prosecution Strategy Guide

Executive Summary

Examiner HELM, CARALYNNE E works in Art Unit 1615 and has examined 828 patent applications in our dataset. With an allowance rate of 29.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.

Allowance Patterns

Examiner HELM, CARALYNNE E's allowance rate of 29.0% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HELM, CARALYNNE E receive 2.89 office actions before reaching final disposition. This places the examiner in the 84% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HELM, CARALYNNE E is 44 months. This places the examiner in the 14% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +52.0% benefit to allowance rate for applications examined by HELM, CARALYNNE E. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 10.6% of applications are subsequently allowed. This success rate is in the 5% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 16.7% of cases where such amendments are filed. This entry rate is in the 19% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 54.2% of appeals filed. This is in the 25% percentile among all examiners. Of these withdrawals, 55.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 55.7% are granted (fully or in part). This grant rate is in the 57% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.4% of allowed cases (in the 71% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.5% of allowed cases (in the 71% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.